Search
Lovotibeglogene autotemcel
go.drugbank.com/drugs/DB18680ApprovedInvestigational12 years and older to be approved by the FDA. … [A262736,L49256] On December 8, 2023, lovotibeglogene autotemcel was approved by the FDA under the brand name Lyfgenia for the treatment of sickle cell disease (SCD) in patients ages 12 and older who
Clascoterone
go.drugbank.com/drugs/DB12499ApprovedInvestigational[A218846] In August 2020, FDA approved clascoterone for the first-in-class topical treatment of acne (acne vulgaris) in male and female patients 12 years and older. … It binds to androgen receptors with high affinity.
Flotufolastat F-18
go.drugbank.com/drugs/DB17851ApprovedInvestigationalUnlike <sup>68</sup>Ga-labeled PSMA-targeting ligands, <sup>18</sup>F-labeled compounds targeting this protein have a longer half-life and can be produced in larger batches. … [A259846,L46731] In patients with recurrent prostate cancer that require localized treatment, the use of <sup>18</sup>F-labeled ligands for positron emission tomography (PET) offers accurate diagnostic
XL281
go.drugbank.com/drugs/DB05190InvestigationalXL281 is a specific inhibitor of RAF kinases, including the mutant form of B-RAF, which is activated in 60 percent of melanomas, 24-44 percent of thyroid cancers, and 9 percent of colon cancers. … Mutational activation of RAS occurs in about 30 percent of all human tumors, including non-small cell lung, pancreatic, and colon cancer.
Tezacaftor
go.drugbank.com/drugs/DB11712ApprovedInvestigational[L1595] It was developed by Vertex Pharmaceuticals and FDA approved in combination with [ivacaftor] to manage cystic fibrosis.[L6814] This drug was approved by the FDA on February 12, 2018. … [A20298,A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage
Ivacaftor
go.drugbank.com/drugs/DB08820ApprovedInvestigationalIt is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012[L768], and by Health Canada in late 2012. … [A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage
Avapritinib
go.drugbank.com/drugs/DB15233ApprovedInvestigational[A189339,L40363] It is one of the first medications available for the treatment of multidrug resistant cancers.[A189327] Avapritinib shares a similar mechanism with [ripretinib].
Streptococcus pneumoniae type 19a capsular polysaccharide antigen
go.drugbank.com/drugs/DB10337ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: Prevnar 20, PNEUMOVAX 23 0,5 ML ENJEKSIYONLUK COZELTI ICEREN FLAKON, 1 ADETTechnetium Tc-99m disofenin
go.drugbank.com/drugs/DB09164ApprovedWithdrawnIt is available as an intravenous injection in a preparation kit under the name Hepatolite. … Technetium Tc-99m is a metastable nuclear isomer and disofenin is an iminodiacetic acid derivative with no known pharmacologic actions at the doses recommended.
Bempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigational[L12144,L12147] It was developed by Esperion Therapeutics Inc. and approved by the FDA on February 21, 2020.